Medicaid coverage of highly effective disease-modifying therapies (DMTs) for multiple sclerosis (MS) varies across the U.S., with some states offering no access at all, a study reported. The research suggests that where a person lives could influence whether they receive high-efficacy therapies, which are known to better control disease activity and slow disability progression. Mihir […]
The post AAN 2026: Top-tier MS drugs out of reach for many on Medicaid appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com